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Abstract
Background: Hepatocellular carcinoma (HCC) develops in a complex microenvironment characterized by chronic
inflammation. In recent years, cholesterol metabolic abnormalities have been implicated the importance in cancer
cell physiology. This study was designed to investigate the relationship between inflammation and cholesterol
accumulation in HCC cells.
Methods: Human HCC cells HepG2 and Huh7 were cultured and stimulated with lipopolysaccharide (LPS) for 24 h.
The changes of HCC cells related to cholesterol metabolism including intracellular cholesterol concentrations,
cholesterol uptake, and the expression of cholesterol-related genes 3-hydroxy-3-methylglutaryl-CoA reductase
(HMGCR), LDL receptor (LDLR), sterol regulatory element-binding transcription factor 2 (SREBF2), and proprotein
convertase subtilisin/kexin 9 (PCSK9) were comparatively analyzed. Simultaneously, the effects of nuclear factor-
kappa B (NF-κB) signaling pathway on cholesterol metabolism were clarified by knocking-down of nuclear factor
kappa-B kinase subunit alpha (IKKα) and TGF-beta-activated kinase 1 and MAP3K7-binding protein 3 (TAB3) via RNAi
and microRNA (miR)-195. Subsequently, the roles of cholesterol accumulation in LPS induced pro-inflammatory
effects were further investigated.
Results: Pro-inflammatory factor LPS significantly increased intracellular cholesterol accumulation by upregulating
the expression of HMGCR, LDLR, and SREBF2, while downregulating the expression of PCSK9. These effects were
revealed to depend on NF-κB signaling pathway by knocking-down and overexpression of IKKα and TAB3.
Additionally, miR-195, a regulator directly targeting IKKα and TAB3, blocked the effects of cholesterol accumulation,
further supporting the critical role of pro-inflammation NF-κB signaling in regulating cholesterol accumulation.
Intriguingly, the accumulation of cholesterol conversely exerted an augmented pro-inflammation effects by further
activating NF-κB signaling pathway.
Conclusions: These results indicated that pro-inflammation effects of NF-κB signaling could be augmented by a
positive feedback via enhancing the cholesterol accumulation in liver cancer cells.
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Background
Metabolic reprogramming in the uncontrolled prolifera-
tion of cancer cells has been thought to play important
roles in cancer biology [1]. Recently, many studies have
demonstrated that cholesterol accumulate in a series of
human cancers, including breast [2], colon [3], prostate
[4], HCC [5], and others [6]. In addition, enzymes involved
in cholesterol metabolism have been reported abnormal
expression in cancer tissues [7, 8]. For instance, choles-
terol acyltransferase (ACAT)2, is found to be induced and
promotes esterification of excess oxysterols for secretion
to avoid cytotoxicity in a subset of hepatocellular carcin-
omas (HCCs) for tumor growth [9], suggestive of a spe-
cific cholesterol metabolic pathway in HCCs. On the one
hand, cholesterol is needed for the synthesis of mem-
branes, signaling molecules, lipid raft formation, and other
factors to support the rapid growth of tumor cells [8]. On
the other hand, cholesterol oxidized products, namely
oxysterols, exhibit inhibitory activities in cell growth and
promote cell apoptosis and dampen antitumor responses
[10–12]. However, mechanism and pathological signifi-
cance underlying the aberrant cholesterol metabolism are
still elusive.
Epidemiological studies have shown that 80% of HCCs
develop in fibrotic or cirrhotic livers as a consequence of
chronic liver injury [13, 14]. The NF-κB pathway, the
key link of inflammatory responses, plays an important
role in HCC promotion by increasing proliferation and
preventing apoptosis [15]. In the inactive state, NF-κB
transcription factors are complexed in the cytoplasm,
either with members of the inhibitor of κB (IκB) family
(in the canonical pathway) or with the NF-κB precursor
p100 (in the non-canonical pathway). Lipopolysaccharide
(LPS), a component of the gram-negative bacterial wall,
could activate NF-κB pathway and stimulate inflamma-
tory responses. Previous studies have demonstrated that
LPS/NF-κB signaling pathway promotes atherosclerotic
progression and macrophage foam cell formation by in-
creasing intracellular cholesterol accumulation [16, 17].
These reports inspired us to hypothesize whether there
is a crosstalk between NF-κB signaling and cholesterol
metabolism in cancer cells.
In the present study, we investigated the relationship
between inflammation and cholesterol metabolism, and
found that pro-inflammatory factor Lipopolysaccharide
(LPS) increased intracellular cholesterol accumulation
through NF-κB pathway in HCC cells. Cholesterol accu-




Human HCC cells HepG2 and Huh7 were purchased
from Cell Bank of the institute of Biochemistry and Cell
Biology, China Academy of Sciences, Shanghai, China.
Cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 10% (v/v) fetal
bovine serum (Gibco, BRL, USA), 10ug/mL strepto-
mycin sulfate and 100ug/mL penicillin G. All cells were
incubated at 37 °C in a humidified atmosphere contain-
ing 5% CO2.
LDL preparation
LDL was purchased from AngYu Biotechnologies
(Shanghai, China). It is isolated from blood bank pro-
duced human plasma. It is purified via ultracentrifugation
to homogeneity determined by agarose gel electrophoresis.
Each lot is analyzed on agarose gel electrophoresis for mi-
gration versus LDL.
Measurement of intracellular cholesterol
Total cellular cholesterol measurement was determined
with a detection kit from Applygen (Peking, China) ac-
cording to the manufacturer’s protocol. Intracellular
lipids were extracted using a chloroform-methanol (2:1)
mix and dried under vacuum. Total cholesterol contents
were measured by an enzymatic assay. The value was
normalized against total protein concentration from
each sample, as determined with Bicinchoninic Acid
assay (Beyotime biotechnology, China).
DIL-LDL uptake
The low density lipoprotein labeled with 1,1′-Dioctade-
cyl-3,3,3′,3′-tetramethyl- indocarbocyanideperchlorate
(DIL-LDL) (Biomedical Technologies Inc., MA, USA)
uptake represented the ability of cell cholesterol uptake.
HCC cells were treated with different addressment, then
changed to serum-free medium and incubated with
10ug/ml DIL-LDL at 37 °C for 5 h. The cells were de-
tached by trypsin, washed and suspended by PBS and
analyzed by flow cytometry using FL2 emission filter
(FACScan, BD Biosciences, San Jose, CA, USA). Data
were analyzed with FlowJo software.
Total RNA isolation and quantitative real-time quantita-
tive PCR
Total RNA, containing miRNA, was isolated from HCC
cells with TRIzol reagent (Invitrogen, CA, USA) according
to the provided protocol. For mRNA analysis, comple-
mentary DNA was synthesized using reverse transcription
reagent kit (TaKaRa, Japan) from RNA of 500 ng. Primers
for PCR were shown in Table 1. Quantitative PCR amplifi-
cation was performed by ABI7500 real-time fluorescent
measurement system (Applied Biosystems, USA) using
PCR amplification Kit (TaKaRa, Japan). Values are derived
from at least 3 separate experiments performed in dupli-
cate and normalized to β-actin expression. The 2-△△Ct
method was used for the data analysis [18]. For miRNA
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analysis, the first-strand cDNA was synthesized using the
reverse transcriptase with miRNAs-specific stem-loop pri-
mer (RiboBio, Guangzhou, China). PCR amplification was
conducted in ABI7500 real-time fluorescent measurement
system (Applied Biosystems, USA) using the Bulge-Loop
miRNA qRT-PCR Starter Kit (RiboBio, Guangzhou,
China) according to the protocol provided. The relative
expression level of miRNA was normalized to that of en-
dogenous control U6 by using 2-△△Ct method.
Western blot
HCC cells were lysed in cell lysis buffer containing 1nM
PMSF for 30 min at 4 °C. Lysates were collected by centri-
fugation at 12,000 rpm for 30 min at 4 °C. Proteins from
cell lysates were separated on the SDS-PAGE and trans-
ferred onto PVDF membrane (Immobion-P Transfer Mem-
brane, Millipore Corp., Billerica, MA, USA). The
membrane was blocked with TBST containing 5% non-fat
dry milk for 1 h and further incubated overnight at 4 °C
with primary antibodies against PCSK9, LDLR, HMGCR,
SREBF2 (Abcam, Cambridge, MA, USA), NF-κB p65,
phospho-NF-κB p65, IKKα, TAB3 (Cell Signaling Technol-
ogy, USA) and β-actin (Santa Cruz, CA, USA). After that,
the membrane was incubated with horseradish peroxidase
(HRP)-linked secondary antibodies (Santa Cruz Biotechnol-
ogy, USA) for 2 h at room temperature. All protein bands
were visualized using an electrochemiluminescence kit
(Thermo, USA). Intensity of each protein band was quanti-
fied by Quantity One 4.6.2 software (Bio Rad).
MiRNA inhibitor or mimic transfection
For transfections in 12-well plates, the HCC cells were
seeded at a density of 1 × 105 cells/well and incubated
overnight and then transfected with 50 nM miR-195
mimic or 100 nM miR-195 inhibitor (GenePharma,
Shanghai, China) using lipo2000 Transfection Agent
(Invitrogen, USA) according to the manufacturer’s in-
structions. The corresponding negative sequence of
mimic or inhibitors (GenePharma, Shanghai, China)
were transfected with the same concentration as con-
trols. At 24 h after the transfection, cells were harvested
or further incubated with LPS (1000 ng/mL) for the fol-
lowing experiments.
RNA interference
Gene silencing was performed by infecting HCC cells with
siRNA oligonucleotides (GenePharma, Shanghai, China).
The siRNA sequences were shown in Table 2. For trans-
fections in 12-well plates, 1.0 × 105 cells were seeded per
well and incubated overnight, then transfected with 80nM
TAB3-siRNA, IKKα-siRNA or negative sequence using
lipo2000 Transfection Agent (Invitrogen, USA) according
to the manufacturer’s protocol. At 24 h after the transfec-
tion, cells were harvested or further incubated with LPS
(1000 ng/mL) for the following experiments.
ELISA
HCC cells were stimulated with LPS (1000 ng/ml) for
24 h in serum-free medium in the presence or absence
of LDL (200ug/ml). The concentrations of IL-8 and
TNF-α in culture supernatants were measured with
ELISA kits (R&D Systems, USA) according to the manu-
facturer’s instruction. Absorbance was recorded at
450 nm using a microplate reader.
Statistical analysis
Data analysis was performed using SPSS16.0 statistical
software (SPSS Inc, Chicago, IL). Student’s t-tests were
Table 1 Primers for PCR used in this study
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used to assess significant differences among study
groups. P < 0.05 was considered statistically signifi-
cant. All experiments have been performed at least
three times.
Results
Role of NF-κB signaling in cholesterol accumulation
To assess whether cholesterol metabolism could be
affected by NF-κB pathway in HCC cells, we moni-
tored intracellular cholesterol levels in response to
LPS at dosages ranging from 0 to 1000 ng/ml in
serum free (SF) medium or complete medium (CM)
or CM with LDL loading (200 μg/ml). As shown in
Fig. 1a and b, LPS significantly increased the intracel-
lular cholesterol concentration in a dose-dependent
manner in HepG2 and Huh7 HCC cells. And the ef-
fects were not affected by constitutive cholesterol
levels. Furthermore, we found that uptake of 3,3′-
dioctadecylindocarbocyanine-low density lipoprotein
(DIL-LDL) in HCC cells was stimulated by LPS, sug-
gesting that it may increase native LDL cholesterol
uptake via LDLR (Fig. 1c and d).
Next, we examined the effect of LPS on the expression
of proprotein convertase subtilisin/kexin 9 (PCSK9),
Table 2 The sequences of siRNA used in this study
Identifier Sense Primer Sequence (5′→ 3′) Anti-sense Primer Sequence (3′→ 5′)
NC siRNA CCACCUCUGAUCGAUUUAUdTdT dTdTAUAAAUCGAUCAGAGGUGG
IKKα siRNA GCAGGCUCUUUCAGGGACAdTdT dTdTCGUCCGAGAAAGUCCCUGU
TAB3 siRNA CCAAAGGUUCCAUGAAGAAdTdT dTdTGGUUUCCAAGGUACUUCUU
Fig. 1 Effects of LPS on cholesterol metabolism in HCC cells. a, b Cells treated with 0, 10, 100, 1000 ng/ml LPS in serum free (SF) medium or
complete medium (CM) in the absence or presence of LDL (200 ug/ml) for 24 h, the total cholesterol ester concentration was measured; c, d
Cells treated with 0, 10, 100, 1000 ng/ml LPS for 24 h. DIL-LDL uptake was detected. Data represent the mean ± SD of triplicate
samples; **P < 0.01
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LDLR, HMGCR and sterol regulatory element-binding
transcription factor 2 (SREBF2) in HCC cells (Fig. 2a-c).
After treatment with various concentrations of LPS for
24 h, PCSK9 mRNA and protein levels in HCC cells
were significantly downregulated, and the expression of
LDLR, HMGCR and SREBF2 were upregulated in a
dose-dependent manner. In addition, LPS promotes the
expression of IKKα, TAB3 and phosphorylated P65
(Fig. 2c), demonstrating the role of NF-κB pathway in
HCC intracellular cholesterol accumulation.
IKKα and TAB3 regulates LPS-induced cholesterol
accumulation
To further examine whether LPS mediated cholesterol
accumulation by NF-κB pathway, we synthesized siR-
NAs specifically against nuclear factor kappa-B kinase
subunit alpha (IKKα) and TGF-beta-activated kinase 1
and MAP3K7-binding protein 3 (TAB3) and overex-
pressed IKKα and TAB3 in HepG2 and Huh7 cells.
The down- and up-regulated efficacy of TAB3 and
IKKα was confirmed by quantitative real-time PCR
and western blotting (Fig. 3a and b). Twenty-four
hours after transfection, HCC cells were treated with
LPS (1000 ng/ml) for 24 h, and PCSK9, LDLR,
HMGCR, and SREBF2 expression, total cellular chol-
esterol levels, and uptake of DIL-LDL were measured
at the endpoints. As expected, down-regulation of
TAB3 and IKKα increased PCSK9 expression and de-
creased LDLR, HMGCR, and SREBF2 expression,
while up-regulation of TAB3 and IKKα decreased
PCSK9 expression and increased LDLR, HMGCR, and
SREBF2 expression (Fig. 3c-e). Additionally, down-
Fig. 2 Expression of PCSK9, LDLR, HMGCR and SREBF2 in HCC cells stimulated with LPS. Cells treated with 0, 10, 100, 1000 ng/ml LPS for 24 h.
The expression of PCSK9, LDLR, HMGCR, SREBF2 and the phosphorylation status of P65 were detected by qRT-PCR (a, b) and western blot (c).
Data represent the mean ± SD of triplicate samples; *P < 0.05, **P < 0.01
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regulation of TAB3 and IKKα abrogated the effects of
LPS on cholesterol accumulation (Fig. 4a–c). These
findings indicated that TAB3 and IKKα were indeed
functional in LPS-induced cholesterol accumulation.
MiR-195 regulates cholesterol accumulation and
cholesterol-related gene expression induced by LPS
Previous findings have shown that miR-195 decreases
the activity of NF-κB signaling and the expression of
Fig. 3 IKKα and TAB3 regulates cholesterol-related gene expression induced by LPS. a, b qRT-PCR and western blotting confirm the down- and
up-regulation of IKKα or TAB3 expression in HCC cells. c, d, e Twenty-four hours after transfection, HCC cells were treated with LPS (1000 ng/ml)
for 24 h, and then PCSK9, LDLR, HMGCR and SREBF2 expression were detected. Data represent the mean ± SD of triplicate samples;
*P < 0.05, **P < 0.01
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NF-κB downstream effectors by directly targeting TAB3
and IKKα [19]. To further investigate the involvement of
NF-κB signaling in cholesterol metabolism, the cells
overexpressing or knocking down miR-195 were estab-
lished by transfecting with miR-195 mimic, mir-195 in-
hibitor. As shown in Fig. 5a, these cells achieved more
than a 100-fold upregulation and 80% downregulation of
mRNA expression, respectively (Fig. 5a). Twenty-four
hours after transfection with miR-195 mimic, miR-195
inhibitor, or negative control, HCC cells were treated
with 1000 ng/mL LPS for another 24 h and then ana-
lyzed for intracellular cholesterol levels and related gene
expression. Relative to the controls, mRNA and protein
expression levels of PCSK9 were downregulated by LPS,
and LDLR, HMGCR, and SREBF2 expression was upreg-
ulated. Overexpression of miR-195 increased PCSK9 ex-
pression and decreased LDLR, HMGCR, and SREBF2
expression, while knockdown of miR-195 decreased
PCSK9 expression and increased LDLR, HMGCR, and
SREBF2 expression (Figs. 5b–d). In addition, overexpres-
sion of miR-195 inhibited the total intracellular choles-
terol level (Fig. 6a and b) and DIL-LDL uptake (Fig. 6c).
These data indicate that miR-195 negatively regulates
LPS-induced cholesterol accumulation and expression of
cholesterol-related genes.
Next, we investigated the phosphorylation status of
p65 and the expression levels of TAB3 and IKKα, which
were the direct gene targets of miR-195. We observed
that overexpression of miR-195 significantly inhibited
the phosphorylation status of p65 and the expression
levels of TAB3 and IKKα, while knockdown of miR-195
increased the phosphorylation status of p65 and the ex-
pression levels of TAB3 and IKKα (Fig. 7), supporting
our findings that NF-κB pathway played an important
role in HCC intracellular cholesterol accumulation.
Cholesterol increases LPS induced pro-inflammatory
effects
LDL, containing 49% cholesterol, could increases intra-
cellular cholesterol contents in HCC cells (Fig. 8a). To
elucidate the influence of cholesterol accumulation in
inflammatory responses, we investigated the phosphoryl-
ation status of NF-κB signaling pathway and the expres-
sion levels of 20 NF-κB downstream effectors in the
absence or presence of LDL loading. LPS at 1000 ng/ml
activated NF-κB signaling pathway and stimulated the
expression of NF-κB downstream effectors, while the
phosphorylation level of p65 and IKKα (Fig. 8b) and the
mRNA abundance of six effectors (Fig. 8c and d) and cy-
tokines production (Fig. 8e and f) was further increased
Fig. 4 Down-regulation of IKKα and TAB3 expression suppressed LPS-induced cholesterol accumulation. a After transfection with IKKα, TAB3 siRNA or
negative control for 24 h, cells treated with 1000 ng/ml LPS in serum free medium or complete medium in the absence or presence of LDL (200 ug/
ml) for 24 h, then the total cholesterol ester concentration was measured. b, c After transfection with IKKα, TAB3 siRNA or negative control for 24 h,
cells were exposed to LPS (1000 ng/mL) for 24 h, then DIL-LDL uptake was detected. Data represent the mean ± SD of triplicate samples; **P < 0.01
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Fig. 5 MiR-195 regulated cholesterol-related gene expression induced by LPS. a validation of miR-195 mimic and inhibitor by qRT-PCR at 24 h after
transfection (b-d) After transfection with miR-195 mimic or inhibitor for 24 h, cells were exposed to LPS (1000 ng/mL) for 24 h. The expression levels of
PCSK9, LDLR, HMGCR and SREBF2 in HCC cells were detected by qRT-PCR (b, c) and western blot (d). Data represent the mean ± SD of triplicate
samples; *P < 0.05, **P < 0.01
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by LDL at 200ug/ml in both HepG2 and Huh7 cells.
The data suggest that accumulated cholesterol increases
LPS/NF-κB-induced inflammatory effects by increasing
p-IKKα in HCC cells.
Discussion
HCC, among the most malignant of human cancers
[20], develops in a complex microenvironment charac-
terized by chronic inflammation [13, 14]. Emerging evi-
dence has demonstrated that perpetuating hepatic
inflammation promotes HCC initiation and progression
[13, 21, 22]. Meanwhile, cholesterol metabolic abnormal-
ities have been implicated the importance in cancer cell
physiology in recent years [2–4, 23]. However, the rela-
tionship between the aberrant cholesterol metabolism
and inflammation in HCCs are not completely under-
stood. In the present study, we demonstrated that LPS/
NF-κB pathway induced a significant increase in the intra-
cellular cholesterol concentration and in DIL-LDL uptake
in HCC cells, suggesting a key role of NF-κB pathway in
promoting cholesterol accumulation. Additionally, the
cholesterol accumulation conversely promoted LPS/NF-
κB-induced inflammatory effects, indicating a positive
feedback of inflammation and cholesterol metabolism
(Fig. 9).
MicroRNAs (miRNAs) are a class of small non-coding
RNAs, which repress translation or induce cleavage of
target mRNAs by base pairing with their 3′ untranslated
regions. MiR-195 is a member of the miR-15/16/195/
424/497 family [24]. It has been reported that miR-195
suppresses cancer development and is downregulated in
multiple types of cancer, such as prostate [25, 26], lung
[27], osteosarcoma [28], HCCs [29], and so forth.
Genome-wide screening suggests that miR-195 mediates
Fig. 6 MiR-195 inhibited LPS-mediated cholesterol accumulation. a, b After transfection with miR-195 mimic for 24 h, cells treated with 1000 ng/ml
LPS in serum free medium or complete medium in the absence or presence of LDL (200 ug/ml) for 24 h, then the total cholesterol ester concentration
was measured. c, d After transfection with miR-195 mimic for 24 h, cells were exposed to LPS (1000 ng/mL) for 24 h. DIL-LDL uptake was detected.
Data represent the mean ± SD of triplicate samples; **P < 0.01
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NF-κB activity by directly targeting the expression of
IKKα TAB3 in HCCs [19]. Here, we demonstrated that
not only miR-195 but also its targeted genes TAB3 and
IKKα mediate LPS/NF-κB-induced cholesterol accumu-
lation and cholesterol-related gene expression, providing
further evidence that NF-κB pathway play an important
role in HCC intracellular cholesterol accumulation.
PCSK9, the ninth member of the proteinase K subfamily
of subtilases, plays an important role in post-transcriptional
degradation of LDLR, which decreases intracellular
cholesterol uptake [30–32]. Decreased PCSK9 and in-
creased LDLR expression have been demonstrated in HCC
tissues, supporting a constant cholesterol supply in the
HCC microenvironment [33]. HMGCR is the rate-limiting
enzyme in de novo synthesis of cholesterol in vivo. Recent
studies have reported that HMGCR is upregulated in
several types of cancer including gastric [34], ovarian [7]
and breast cancers [35], suggesting that HMGCR plays an
oncogenic role. SREBF2 is a membrane-bound transcrip-
tion factor that regulates cholesterol homeostasis in cells. It
Fig. 7 MiR-195 inhibited the activation of NF-κB pathway. a, b, c After transfection with miR-195 mimic for 24 h, cells treated with 1000 ng/ml
LPS for 24 h, then the phosphorylation status of P65 and the expression levels of TAB3 and IKKα were detected by western blot. Data represent
the mean ± SD of triplicate samples; *P < 0.05, **P < 0.01
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Fig. 8 LDL increases LPS induced pro-inflammatory effects. LDL increases intracellular cholesterol contents (a), LDL significantly activated the
phosphorylation of p65 and IKKα (b), increased the expression of NF-κB target genes (c, d), promoted the production of IL-8 and TNF-α in HCC
cells with administration of LPS for 24 h (e, f). Data represent the mean ± SD of triplicate samples; *P < 0.05, **P < 0.01
Fig. 9 Illustration of the schematic representation of the working
He et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:15 Page 11 of 13
has been demonstrated that PCSK9, LDLR, and HMGCR
expression are co-regulated by SREBF2 [36–38]. When
cholesterol levels fall, SREBF2 is activated to up-regulate
the expression of genes responsible for cholesterol synthe-
sis, such as HMGCR, and for cholesterol uptake, such as
LDLR. In this study, the expression of PCSK9, LDLR,
HMGCR, and SREBF2 were investigated in HCC cells after
stimulation with LPS. We found that LPS significantly
inhibited the expression of PCSK9 and increased LDLR,
HMGCR, and SREBF2 expression, suggesting that LPS may
increase native LDL cholesterol uptake via LDLR and pro-
mote de novo cholesterol synthesis via HMGCR.
There are growing evidences that cholesterol, as an
important molecule, impacts upon cancer cell physi-
ology, however, the concrete role of cholesterol in cancer
progression remains elusive and controversial. Analyses
of the cancer Genome Atlas (TCGA) database revealed a
correlation between increased activity of the cholesterol
synthesis pathway and decreased survival in patients
with sarcoma, acute myeloid leukemia and melanoma
[39, 40], supporting the concept that cholesterol pro-
motes carcinogenesis. However, some epidemiological
studies have reported objective observation that poor
prognosis in HCC patients were linked to decreased
serum cholesterol [41, 42]. In this study, we have sug-
gested that cholesterol further activated the NF-κB sig-
naling pathway and promotes the expression of NF-κB
target genes, indicating the pro-inflammatory effects of
cholesterol in HCC cells.
Conclusions
In summary, we have experimentally demonstrated that
LPS/NF-κB signaling pathway triggers an increase in
intracellular cholesterol levels by promoting the expres-
sion of HMGCR and LDLR in HCC cells. Cholesterol
accumulation conversely promotes LPS/NF-κB induced
pro-inflammatory effects. MiR-195, as a regulator of NF-
κB pathway, inhibited cholesterol accumulation by de-
creasing the expression of TAB3 and IKKα. These data
provide us with a better understanding of the relation-
ship between LPS/NF-κB pathway and cholesterol ab-
normalities in cancer cells.
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